Integration a Key Aspect of Roche/Genentech Proposal Pharma Can Support, Not Stifle Innovation As the details of Roche Holding AG's $43.7 billion proposal to acquire Genentech Inc.unfolded on Monday, integration emerged as a key aspect of the deal.
In a conference call, Roche Chairman...
Leading NZ scientist dies Ross Clark, one of New Zealand's top scientists, has died in Auckland, aged 57.Professor Clark had fought a long battle with malignant melanoma.
Close friend, colleague and BioPacificVentures executive director Howard Moore said...
Tercica founder Ross Clark dies Tercica Inc.founder Ross Clark died Sunday at his home in Auckland, New Zealand, after a long battle with malignant melanoma.
Clark, 57, founded Brisbane-based Tercica (NASDAQ: TRCA) in New Zealand in September 2000.
French drugmaker...
Tercica founder Ross Clark dies San Francisco Business Times - by Ron Leuty Related News Anesiva CEO quits [San Francisco] Local president injects new energy into Takeda S.F.[San Francisco] Genentech and MedImmune settle patent fight [San Francisco] Ipsen buys Tercica...
Tercica founder Ross Clark dies Tercica Inc.founder Ross Clark died Sunday at his home in Auckland, New Zealand, after a long battle with malignant melanoma.
Clark, 57, founded Brisbane-based Tercica (NASDAQ: TRCA) in New Zealand in September 2000.
French drugmaker...
Tercica founder Ross Clark dies Tercica Inc.founder Ross Clark died Sunday at his home in Auckland, New Zealand, after a long battle with malignant melanoma.
Clark, 57, founded Brisbane-based Tercica (NASDAQ: TRCA) in New Zealand in September 2000.
French drugmaker...
Tercica Announces Results from Increlex IGFD Patient Registry and Other Increlex Studies at the 90th Meeting o - Tercica, Inc.(NASDAQ: TRCA) today announced the first results from the Increlex(R) Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco.
Increlex(R) ...
Ispen expands US operations by acquiring Tercica Ipsen has taken significant steps forward in building a fully fledged commercial presence in North America.In line with its strategy to globalize its specialist care business, the three transactions announced will allow Ipsen, upon...
